title: Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions.
abstract: We studied the expression of both fibroblast growth factor-2 (FGF-2) and FGF receptor-1 (FGFR-1) in various histological types of human thyroid neoplastic and hyperplastic tissues to clarify the biological behavior of FGF-2. A total of 37 malignant tumors (24 papillary carcinomas, 10 follicular carcinomas, 3 anaplastic carcinomas), 8 follicular adenomas, and 12 adenomatous goiters were examined by immunohistochemical methods. With immunohistochemical staining, both FGF-2 and FGFR-1 were frequently detected in human thyroid carcinoma (79.2 to 100% and 80 to 100%, respectively). In thyroid hyperplastic lesions such as adenomatous goiter, the FGF-2 immunoreactivity in follicular cells was detected in 2 of 12 adenomatous goiters (16.7%). In contrast, FGFR-1 immunoreactivity was detected in 66.7% of cases of this disease. The endothelial cells of microvessels in the stroma adjacent to the neoplasms and hyperplastic lesions also showed cytoplasmic FGF-2 immunoreactivity. The difference between FGF-2 and FGFR-1 expression in adenomatous goiters was statistically significant (P<0.05). Furthermore, the difference in FGF-2 immunoreactivity between carcinoma and adenomatous goiter was statistically significant (P=0.0001). The present investigation demonstrated the possibility of an autocrine mechanism of action of FGF-2 in human thyroid carcinoma. Moreover, in thyroid hyperplastic lesions, FGF-2 derived from the stroma might be involved in the formation of nodular and/or diffuse goiters.
authors.affiliation: Department of Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shingu
authors.forename: M
authors.initials: M
authors.lastname: Fujimori
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Hama
authors.forename: Y
authors.initials: Y
authors.lastname: Kasuga
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: N
authors.initials: N
authors.lastname: Itoh
authors.forename: J
authors.initials: J
authors.lastname: Amano
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000737:chemistry; D000236:Adenoma / Q000737:chemistry; D015153:Blotting, Western; D002277:Carcinoma / Q000737:chemistry; D002291:Carcinoma, Papillary / Q000737:chemistry; D004730:Endothelium, Vascular / Q000737:chemistry; D016222:Fibroblast Growth Factor 2 / Q000032:analysis*; D006042:Goiter / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D017468:Receptors, Fibroblast Growth Factor / Q000032:analysis*; D013959:Thyroid Diseases / Q000378:metabolism*; D013961:Thyroid Gland / Q000737:chemistry; D013964:Thyroid Neoplasms / Q000737:chemistry
chemical_list: D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2; C496348:FGFR1 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1